Abstract
To the Editor: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects intertriginous areas. Adalimumab is United States Food and Drug Administration-approved for HS treatment, but other tumor necrosis factor-α inhibitors (TNFIs) may be effective.1 Tuberculosis (TB) reactivation risk is well known in patients taking TNFIs, and latent tuberculosis infection (LTBI) screening before TNFI initiation is recommended. Several organizations additionally recommend annual LTBI screening in patients taking biologics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
